News about "Zydus Lifesciences"

Zydus Lifesciences Reports 22 Percent Revenue Growth in Q1 FY27, Advances Innovation Pipeline

Zydus Lifesciences began FY27 with strong double-digit growth, driven by robust performance across India and international formulations, alongside continued progress in manufacturing quality and biosimilar innovation.

Zydus Lifesciences | 12/08/2026 | By News Bureau

Zydus Launches REVAHALE, India's First Once-Daily Nebulised LAMA for COPD

Zydus launches REVAHALE (revefenacin), India’s first once-daily nebulised LAMA for COPD, offering sustained 24-hour bronchodilation through nebulised delivery.

Zydus Lifesciences | 11/08/2026 | By News Bureau

Zydus Wins US FDA Approval for Generic Indocyanine Green Injection

Zydus has received US Food and Drug Administration (FDA) approval for generic Indocyanine Green Injection, expanding its injectable imaging portfolio and functional dyes business.

Zydus Lifesciences | 06/08/2026 | By News Bureau

Torrent Pharma Recalls Select Semalix Injection Batches Following API-Related Quality Issue

Torrent Pharmaceuticals has initiated a recall of select batches of Semalix Injection 2 mg and 4 mg after certain semaglutide batches failed quality specifications due to an API-related issue.

Zydus Lifesciences | 10/07/2026 | By News Bureau |  171

Zydus Lifesciences and Sunshine Healthcare Form JV to Boost Pharma Manufacturing in Sri Lanka

Zydus Lifesciences and Sunshine Healthcare launch a Joint Venture (JV) to develop a pharma manufacturing facility at BOI Horana, strengthening Sri Lanka’s supply of quality medicines.

Zydus Lifesciences | 29/06/2026 | By News Bureau |  102

Assertio Announces Completion of Merger with Zydus Lifesciences

Assertio has completed its merger with Zydus Lifesciences, becoming a wholly owned subsidiary of the company. Following the acquisition, Assertio shares have been delisted from Nasdaq, with shareholders receiving USD 23.50 per share in cash.

Zydus Lifesciences | 19/06/2026 | By News Bureau |  113

US FDA Grants Priority Review to Zydus Therapeutics' Saroglitazar for Primary Biliary Cholangitis

Zydus Therapeutics has received US FDA Priority Review (PR) for its New Drug Application (NDA) for saroglitazar in the treatment of Primary Biliary Cholangitis (PBC), supported by phase 3 EPICS-III trial results demonstrating significant biochemical response, with detailed data to be presented at the EASL Congress 2026.

Zydus Lifesciences | 29/05/2026 | By News Bureau |  157

Zydus Lifesciences Completes Investment in Torrent Urja 25 with Rs 90.18 Million Share Subscription

Zydus Lifesciences and its subsidiaries have completed the final tranche of investment in Torrent Urja 25, subscribing to equity shares worth Rs 90.18 million and concluding the transaction initiated under the Share Subscription and Shareholders’ Agreements (SSSAs).

Zydus Lifesciences | 20/05/2026 | By News Bureau |  161

Zydus Lifesciences Launches Aerolife Mini, India's First Portable Foldable Spacer

Zydus introduces Aerolife Mini, a compact pMDI enhancer designed to improve inhaler drug delivery and patient compliance in respiratory care through a convenient, foldable design.

Zydus Lifesciences | 20/03/2026 | By News Bureau |  184

Zydus and Torrent Pharma Sign Licensing Deal to Co-Market Semaglutide in India

Zydus Lifesciences and Torrent Pharmaceuticals have entered a licensing agreement to co-market Semaglutide injection in India, aiming to improve access for patients with poorly controlled Type 2 Diabetes Mellitus and support chronic weight management through advanced, innovative therapy.

Zydus Lifesciences | 19/03/2026 | By News Bureau |  230